Serum amyloid P component level is associated with clinical response to escitalopram treatment in patients with major depressive disorder. (February 2022)

• Record Type: Journal Article
• Authors: Yang, Jian; Zhou, Jingjing; Zhou, Jia; Wang, Haixia; Sun, Zuoli; Zhu, Xuequan; He, Yi; Wong, Albert H.C.; Liu, Fang; Wang, Gang
• Is Part Of: Journal of psychiatric research. Volume 146(2022)
• Page Start: 172
• Page End: 178
• Publication Date: 2022-02
• Subjects: Major depressive disorder -- Serum amyloid P component -- Escitalopram -- Treatment response; Psychiatry -- Periodicals; Mental Disorders -- Periodicals; Maladies mentales -- Périodiques; Psychiatry; Electronic journals; Periodicals; 616.89005
• DOI: 10.1016/j.jpsychires.2021.12.051
• Languages: English
• ISSNs: 0022-3956

Abstract

Abstract: Serum amyloid P component (SAP) is a universal constituent of human amyloid deposits, which has been implicated in Alzheimer's disease and major depressive disorder (MDD). However, the relationship between SAP level and depression severity remains obscure. The aims of this study were to investigate how SAP is involved in depression and to explore the association between SAP level and antidepressant treatment response. Patients with MDD (n = 85) who received escitalopram monotherapy for 8–12 weeks were selected from a multicenter open-label randomized clinical trial. The same number of healthy controls was recruited. Depression severity was measured according to the Hamilton Depression Rating Scale (HAMD-17) at baseline and weeks 4, 8, and 12. The plasma levels of SAP were measured at baseline, week 2 and week 12. As a result, baseline levels of SAP were significantly higher in depressed patients than in control subjects ( p < 0.001). SAP levels at baseline were negatively associated with depression severity after escitalopram treatment ( p < 0.05), and the changes in SAP levels from baseline to week 12 were highly correlated with the severity of depressive symptoms based on the HAMD-17 score ( p < 0.05). Interestingly, treatment with escitalopram significantly decreased the plasma levels of SAP in females, but not in males. Altogether, our results suggest that SAP not only involved in the pathobiology of depression but also mediates the action of antidepressant medications.